Humacyte Q3 net loss $39.2M; ATEV BLA review ongoing with no new timeline

Humacyte, Inc.

2024-Q3 EPS reported -$1.10

Net loss $39.2M (Q3 2024) vs $26.0M (Q3 2023) driven by non-cash contingent earnout remeasurement.
Cash $71M at Sep 30; received $29.6M net from Oct registered direct offering.
FDA BLA for ATEV in vascular trauma still under review; no new PDUFA date provided.
V007 Phase 3 AV access data presented at ASN Kidney Week: ATEV superior patency vs fistula in key subgroups.
Submitted NTAP reimbursement application to CMS for FY2026 cycle (Oct 2025 effective date if approved).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.